Member News

Phosphagenics Signs a Multinational License for TPM® in Personal Care Products

Phosphagenics Signs a Multinational License for TPM® in Personal Care Products 4 December 2017, Melbourne: Australian drug delivery company, Phosphagenics Limited (ASX: POH; OTCQX: PPGNY), is pleased to announce the signing of a non-exclusive license agreement with Rodan…

Job: Senior Quality Assurance Manager

• TGA Licensed Manufacturer • Manage department of 38+ staff • Winner of multiple export awards Our Client Our client is an Australian success story experiencing year on year international growth in over 22 countries. Their mission is…

$2.5M GRANT AWARDED TO ADVANCE WOUNDVUE™ DEVELOPMENT

• Joint collaboration with University of Melbourne and Planet Innovation Adelaide, Australia, 7 December 2017: Australian medical technology company, LBT Innovations Limited (ASX:LBT) is pleased to announce it has been awarded a $2.513 million grant to advance the…

Prima BioMed has just announced new clinical data from its TACTI-mel Phase I trial in Australia – which is investigating Prima’s lead drug, IMP321, in combination with KEYTRUDA in metastatic melanoma

Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima”) is pleased to announce the presentation of new data from its TACTI-mel Phase I clinical trial in Australia investigating the use of eftilagimod alpha (LAG-3Ig or IMP321), the Company’s lead…

IDT Australia Executes API Development Agreement

• API Development Agreement executed with The State Government of Victoria • Total consideration over AUD 2,000,000 over the twelve month term of the project Australian pharmaceutical manufacturing and drug development company IDT Australia Limited (ASX:IDT) announces it…

AdAlta appoints Dr Dallas Hartman as Chief Operating Officer

AdAlta Limited (ASX: 1AD), the biotechnology company advancing its lead i-body candidate towards clinical development, is pleased to announce the appointment of experienced executive, Dr Dallas Hartman to the role of Chief Operating Officer. Dr Hartman will bring…

Patrys and Garvan Institute of Medical Research Awarded Grant

Patrys Limited (ASX: PAB), a clinical stage biotechnology company and Sydney’s Garvan Institute of Medical Research (Garvan) have recently finalized the terms of a Federal Government Innovation Connections grant to support research within the PATDX1 program. The Garvan…

New US patent for Patrys PAT-LM1

Patrys (ASX:PAB), a clinical stage biotechnology company, has been granted a US patent for its anti-cancer pre-clinical candidate PAT-LM1. The US Patent Office has issued correspondence confirming the grant of a key patent in the PAT-LM1 family, patent…

Universal Biosensors receives $7.5M under the R&D Tax Incentive

Universal Biosensors (ASX:UBI) today announced it has received $7.5M in cash under the R&D Tax Incentive for the 2016 financial year. The R&D Tax Incentive is an Australian Government program developed to assist eligible businesses recover some of…

Medical Device Industry Sign Historic Agreement to Reduce Health Fund Premiums

The Medical Technology Association of Australia (MTAA) has signed a four-year Agreement with the Federal Government which will deliver certainty and stability to the industry and will help lower Private Health Insurance (PHI) premiums for Australians. The Agreement,…

GKC names John Schellhorn new President and CEO

GKC announced today that it has appointed John Schellhorn as its new President and CEO. Schellhorn will also be joining the company’s Board of Directors. Schellhorn joins GKC with a proven track record to spearhead the company’s accelerated…

LBT Receives $4.2 Million in R&D Incentives

Australian medical technology company LBT Innovations Limited (ASX:LBT) has received an R&D Incentive, net of income tax payable, of $3.98 Million for the financial year ended 30 June 2017. In addition, LBT has also received $0.22 Million for…

Home

News & opinion

Member Directory

Events